- Home
- SID vs KNSA Comparison
SID vs KNSA Comparison
Compare SID & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SID
- KNSA
- Stock Information
- Founded
- SID 1941
- KNSA 2015
- Country
- SID Brazil
- KNSA United Kingdom
- Employees
- SID N/A
- KNSA N/A
- Industry
- SID Steel/Iron Ore
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- SID Industrials
- KNSA Health Care
- Exchange
- SID Nasdaq
- KNSA Nasdaq
- Market Cap
- SID 1.9B
- KNSA 2.1B
- IPO Year
- SID 1997
- KNSA 2018
- Fundamental
- Price
- SID $1.55
- KNSA $27.88
- Analyst Decision
- SID Strong Sell
- KNSA Strong Buy
- Analyst Count
- SID 1
- KNSA 5
- Target Price
- SID $1.30
- KNSA $38.80
- AVG Volume (30 Days)
- SID 3.1M
- KNSA 1.1M
- Earning Date
- SID 07-31-2025
- KNSA 07-22-2025
- Dividend Yield
- SID 13.51%
- KNSA N/A
- EPS Growth
- SID N/A
- KNSA N/A
- EPS
- SID N/A
- KNSA N/A
- Revenue
- SID $7,828,045,151.00
- KNSA $481,166,000.00
- Revenue This Year
- SID $7.14
- KNSA $37.21
- Revenue Next Year
- SID $3.79
- KNSA $5.32
- P/E Ratio
- SID N/A
- KNSA N/A
- Revenue Growth
- SID 2.40
- KNSA 59.45
- 52 Week Low
- SID $1.27
- KNSA $17.82
- 52 Week High
- SID $2.50
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- SID 56.55
- KNSA 50.38
- Support Level
- SID $1.36
- KNSA $26.89
- Resistance Level
- SID $1.45
- KNSA $27.97
- Average True Range (ATR)
- SID 0.05
- KNSA 0.95
- MACD
- SID 0.01
- KNSA -0.27
- Stochastic Oscillator
- SID 96.00
- KNSA 48.73
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.